Eyes - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Eyes

ALDX, EYPT, NASDAQ, NVS, NYSE, OCUL, OKYO

#Eyes #Third-Party Article

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 2, 2023
08:45

EST

FinancialNewsMedia.com News Commentary PALM BEACH, Fla. , May 2, 2023 /PRNewswire/ — The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the rising prevalence of dry eye disease, the presence of a lucrative pipeline, and increasing awareness

No Comments

KPRX, NASDAQ

#Event #Eyes #Meeting Results #Trending News

Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

May 1, 2023
07:00

EST

Encinitas, California–(Newsfile Corp. – May 1, 2023) – Kiora Pharmaceuticals (NASDAQ: KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled “Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal ‘Photoswitch’ Molecule (KIO-301): Functional

No Comments

NYSE, RAD

#Eyes #Trending News

Rite Aid Looks to ‘Ease the Sneeze’ This Allergy Season

April 26, 2023
08:45

EST

PHILADELPHIA–(BUSINESS WIRE)–It’s no secret seasonal allergies are here. From runny noses and itchy eyes to tissues carried in all pockets and bags, spring has sprung and mother nature has brought the dreaded sneeze with her. To help its suffering shoppers, Rite Aid has spent the last few weeks dusting

No Comments

NASDAQ, STOK

#Eyes #Phase 1/2: Started #Trending News

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 25, 2023
07:00

EST

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a

No Comments

NASDAQ, OCGN

#Eyes #Phase 1/2 #Positive Clinical Trial Results #Trending News

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

April 14, 2023
07:45

EST

Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes 71.4% (5/7) of OCU400 treated eyes in low and medium dose cohorts experienced

No Comments

ADSK, ATUS, BBWI, BIDU, BIRD, BKNG, BMBL, BYND, CAKE, CARS, CBRL, COIN, CPI, CRI, CUBE, CVNA, DDS, DISH, DPZ, EBAY, ETSY, FNF, FOMC, FTCH, HD, INTU, KDP, LCID, LMND, LYV, LZB, MRNA, NASDAQ, NKLA, NYSE, OSTK, OTC, PANW, PCG, PLNT, PZZA, RCII, SHOO, SKT, SQ, TDOC, TJX, TOL, TWNK, UTHR, VAC, W, WBD, WING, WMT, WWW, YETI, ZIP

#Eyes #Financial Data #Third-Party Article

Fed minutes, PCE inflation, Walmart earnings: What to know this week

February 19, 2023
09:23

EST

Earnings from retail giants Walmart (WMT) and the Home Depot (HD) this week, along with the latest update on the Federal Reserve’s preferred inflation measure and the minutes from the Fed’s latest policy meeting will be highlights in the holiday-shortened week ahead. U.S. stock and bond markets will be

No Comments

AYRWF, OTC

#Cannabis #Eyes #New Employee

Ayr Wellness Appoints David Goubert to President & CEO

February 13, 2023
16:30

EST

MIAMI, Feb. 13, 2023 (GLOBE NEWSWIRE) — Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), today announced that Jonathan Sandelman has transitioned to Executive Chair, where he will continue to serve the Company’s Board of Directors, and

No Comments

HEMP, OTC

#Eyes

New Look, New Feel for Hemp, Inc.’s Hempinc.com

January 31, 2023
09:00

EST

LAS VEGAS, NV, Jan. 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Get ready to feast your eyes on Hemp, Inc.’s (OTC PINK: HEMP) newly redesigned website that provides the ultimate user-friendly experience with improved navigation, functionality, and payment processing. Hempinc.com and Kingofhempusa.com are now under one incredible roof to properly align

No Comments

NASDAQ, OCUP

#Event #Eyes #FDA Meeting #New Clinical Trial Data #Phase 2 #Trending News

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

January 25, 2023
16:01

EST

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment Oral APX3330 Demonstrated Favorable Safety and Tolerability Allowing for a Potential Attractive Non-Invasive Option for Protection of Vision in Both Eyes in DR Patients

No Comments

ICAD, NASDAQ

#Eyes #New Employee

iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI

January 23, 2023
08:00

EST

Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA, N.H., Jan. 23, 2023 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors

No Comments

< Page1 Page2 Page3 … Page7 >

Trending News

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

05/26/2023

SILVERCORP DECLARES SEMI-ANNUAL DIVIDEND OF US$0.0125 PER SHARE

05/26/2023

Halo Collective Provides Update on Status of Financial Statements

05/26/2023

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2023

US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer

05/26/2023

Most read news

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease

05/25/2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

05/24/2023

Avante Announces Private Placement Closing

05/24/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account